Skip to main content
. 2016 May 9;7(23):33765–33782. doi: 10.18632/oncotarget.9260

Figure 5. IL-10 neutralization restored the phenotypic and functional maturation of LPS-activated DCs from cisplatin-induced tolerogenic DCs.

Figure 5

A., B., C. BMDCs were treated with a neutralizing anti-IL-10 mAb or rat IgG (isotype control) in the absence or presence of LPS (100 ng/ml) or cisplatin (5 μg/ml). A. After 18 h, TNF-α, IL-12 p70 and IL-10 levels in the culture supernatants were measured by ELISA. B. The cells were harvested, and the surface molecule expression patterns of CD11c+ cells were measured by flow cytometry. C. Endocytic capacity was determined by assessing the endocytosis of FITC-dextran after IL-10 neutralization. The percentages of dextran-FITC positive CD11c+ cells are indicated. All bar graphs show the mean ± SD (n = 3 samples) of one representative plot from three independent experiments. *p < 0.05 and ***p < 0.001 between the anti-IL-10 and IgG isotype control in DCs treated with LPS and cisplatin.